ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer
ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer
Active, not recruiting · NCT05446298 · Registry updated 2026-09-22Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer | Adnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, endocrine system disorder, fallopian tube cancer, fallopian tube disorder, fallopian tube neoplasm, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian disorder, primary peritoneal carcinoma | Active, not recruiting | Phase 2 | 2026-09-22 | NCT05446298 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| GOG Foundation | 38 |
| Merck Sharp & Dohme LLC | 650 |
| OncoC4, Inc. | 8 |
21 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.